Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Anticancer Research|July 23, 1998
Immunocytochemical localization of an immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5-fluoro-2'-deoxyuridine) in human prostate tumorsA A Sinha, B J Quast, M J Wilson, et al.
The Journal of Urology|November 7, 2001
Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasiaT A Stamey, J A Warrington, M C Caldwell, et al.
AJR. American Journal of Roentgenology|January 1, 1987
MR imaging of the prostate gland: normal anatomyH Hricak, G C Dooms, J E McNeal, et al.
The Journal of Urology|September 1, 1986
Analysis of fixation effects on immunohistochemical localization of prostatic specific antigen in human prostateA A Sinha, K A Hagen, R K Sibley, et al.
Anticancer Research|February 1, 2000
The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic scoreA A Sinha, B J Quast, J C Korkowski, et al.
The Prostate|September 6, 2001
Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancerA A Sinha, B J Quast, M J Wilson, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|January 1, 1994
Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993G P Murphy, C Busch, P A Abrahamsson, et al.
The Prostate|January 1, 1989
Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostateA A Sinha, D F Gleason, M J Wilson, et al.
Cancer|June 20, 2001
Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysisM J Barry, P C Albertsen, M A Bagshaw, et al.
Cancer|January 15, 1992
Prediction of prognosis in untreated stage A2 prostatic carcinomaJ L Mohler, A W Partin, J I Epstein, et al.
Pageof 14